SOURCE: IGI, Inc.

August 01, 2006 13:12 ET

IGI, Inc. Announces the Miaj™ Enriching Repair Night Cream Is Highly Effective in Improving Skin Firmness

BUENA, NJ -- (MARKET WIRE) -- August 1, 2006 --IGI, Inc. (AMEX: IG) announces that Miaj™ Enriching Repair Night Cream has been proven to significantly increase skin firmness after only four weeks of use, based on qualitative and quantitative clinical testing conducted by an independent testing facility.

Miaj™ Enriching Repair Night Cream was custom formulated using the patented Novasome® delivery technology creating a luxurious cream that reduces the appearance of fine lines and wrinkles, protects cell structure, and promotes collagen synthesis.

Clinical Results

In a four week clinical study conducted by an independent testing facility, Miaj™ Enriching Repair Night Cream was applied topically once a day to the face to evaluate its potential for skin moisturization, softness, smoothness, fine line reduction, wrinkle reduction and skin firmness.

The results from the use of Miaj™ Enriching Repair Night Cream:

100% reported noticeable improvement in skin moisturization
100% reported noticeable improvement in skin softness
100% reported noticeable improvement in skin smoothness
100% reported noticeable improvement in overall skin appearance
 90% reported noticeable improvement in fine line reduction
 90% reported noticeable improvement in wrinkle reduction
 90% reported noticeable improvement in skin texture
 90% reported noticeable improvement in skin firmness/elasticity
Quantitative Results

Skin firmness was measured at the end of the four week study using Ballistometry. This method involves a Ballistometer which releases a pendulum to the surface of the skin and the resultant bouncing pattern of the pendulum is analyzed by a computer to determine skin firmness. Quantitative results showed a significant 28% increase in skin firmness in just four weeks.

The Miaj™ Enriching Repair Night Cream is part of a new ten product skin care line focusing on anti-aging. The entire Miaj™ product line is now available online at www.miaj.com or by calling (856) 697-1441 ext. 366.

IGI is a company committed to growth by applying proprietary technologies to achieve cost-effective solutions for varied customer needs. IGI offers the patented Novasome® lipid vesicle encapsulation technology which contributes value-added qualities to cosmetics, skin care products, dermatological formulations and other consumer products, providing improved dermal absorption, low potential for irritations, controlled and sustained release as well as improved stability. IGI has licensed Novasome® lipid vesicle encapsulation technology to leading global dermatological and skin care companies including Johnson & Johnson Consumer Products, Inc., Estee Lauder Companies, Chattem Inc., Genesis Pharmaceutical, Inc. and Apollo Pharmaceutical, Inc.

IGI sub-licensed the rights to obtain FDA approval for and market IGI's PTH (1-34) compound using Novasome® lipid vesicle encapsulation technology for psoriasis, which is slated for Phase II clinical trials, to Manhattan Pharmaceuticals, Inc. IGI is also exploring the licensing of the topical PTH (7-34) compound for the prevention/treatment of chemotherapy induced-alopecia in patients undergoing chemotherapy.

This report contains forward-looking statements relating to IGI's hopes and expectations for the future. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "will," "possible," "one time," "provides an opportunity," "continue" and similar expressions are intended to identify forward-looking statements. Such statements involve a number of risks and uncertainties and actual future events and results could differ materially from those indicated by such forward-looking statements due to general economic conditions, and the risk factors detailed in IGI's periodic reports and registration statements filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Frank Gerardi
    Chairman & Chief Executive Officer
    IGI, Inc.
    856-697-1441 ext. 102
    www.askigi.com